In the past, patients with HER2-positive breast cancer generally had unfavorable outcome [2], but this changed radically after discovery of trastuzumab, a recombinant humanized monoclonal antibody that binds to the extracellular subdomain IV of HER2. Here, ERBB2 is linked to breast carcinoma.